EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial

Xiao Quan Huang, Ying Jie Ai, Feng Li iD, Si Tao Ye, Jia Hao Wang, Rui Zhang, Wei Zhang, Yu Li Zhu, Shi Yao Chen iD

Journal of Digestive Diseases · 2024

DOI: 10.1111/1751-2980.13314 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Xiao Quan Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rifaximin, Liver Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Microbiome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Fund of Clinical Research of Zhongshan Hospital, Fudan University, Innovation Fund of Science and Technology Commission of Shanghai Municipality, Shanghai Sailing Program, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The application of rifaximin, a non‐absorbable antibiotic, in hepatic encephalopathy (HE) has been well established; however, its effect on other complications in cirrhotic patients with previous gastroesophageal variceal bleeding (GEVB) remains unclear. Therefore, we performed a pilot randomized controlled trial aiming to evaluate the impact of rifaximin on cirrhosis‐related complications and changes in gastric microbiota.

Methods

Eighty cirrhotic patients who received prophylactic endoscopic treatment for variceal rebleeding were randomly assigned to the control or rifaximin treatment group (rifaximin 400 mg twice daily for 8 weeks). Primary outcome was the total liver‐related score, consisting of changes in cirrhosis‐related complications including rebleeding, ascites, HE and portal vein thrombosis (PVT). The 16S rDNA sequencing analysis was conducted with gastric lavage fluid samples for the analysis of gastric microbiota.

Results

During the 8‐week follow‐up, the total liver‐related score decreased significantly upon rifaximin therapy (−0.35 ± 0.14 vs 0.05 ± 0.14, p = 0.0465) as well as serum C‐reactive protein (CRP) ( p = 0.019) and interleukin‐8 ( p = 0.025) compared with the control group. The rate of PVT recanalization was significantly higher in the rifaximin group ( p = 0.012). Prominent difference in gastric microbiota between the two groups was observed, and the rifaximin group had a higher abundance of several taxa which were dysregulated in the progression of cirrhosis. CRP was correlated with several taxa including Alphaproteobacteria, Rhizobiales and Collinsella.

Conclusions

Rifaximin may improve cirrhosis‐related complications, including PVT, in patients with previous GEVB through anti‐inflammatory and microbiota‐modulating functions. Trial registration number: NCT02991612.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifaximinLiver CirrhosisEsophageal and Gastric VaricesGastrointestinal MicrobiomeGastrointestinal HemorrhageHumansMaleMiddle AgedFemalePilot ProjectsAgedAdultHepatic EncephalopathyTreatment OutcomeStomach

Stichwörter der Autor:innen

esophageal and gastric varicesgastrointestinal microbiomeliver cirrhosisnon‐absorbable antibioticsportal hypertension

Substanzen

Rifaximin

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Center of Evidence-Based Medicine, Fudan University, Shanghai, China.
  • Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
  • Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Feng Li, Shi Yao Chen

Förderung

  • Fund of Clinical Research of Zhongshan Hospital, Fudan University
  • Innovation Fund of Science and Technology Commission of Shanghai Municipality
  • Shanghai Sailing Program, Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Huang, X. Q., Ai, Y. J., Li, F., Ye, S. T., Wang, J. H., Zhang, R., Zhang, W., Zhu, Y. L., & Chen, S. Y. (2024). Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13314

Vancouver

Huang XQ, Ai YJ, Li F, Ye ST, Wang JH, Zhang R, et al. Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13314

BibTeX
@article{Huang2024,
  author = {Huang, Xiao Quan and Ai, Ying Jie and Li, Feng and Ye, Si Tao and Wang, Jia Hao and Zhang, Rui and Zhang, Wei and Zhu, Yu Li and Chen, Shi Yao},
  title = {Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial},
  journal = {Journal of Digestive Diseases},
  year = {2024},
  doi = {10.1111/1751-2980.13314}
}
Kostenlos starten →